A Phase II Study of Regorafenib With a Lower Starting Dose in Patients With Metastatic Colorectal Cancer: Exposure–Toxicity Analysis of Unbound Regorafenib and Its Active Metabolites (RESET Trial)

Clinical Colorectal Cancer

Suzuki T
Sukawa Y
Imamura C
Masuishi T
Satake H
Kumekawa Y
Funakoshi S
Kotaka M
Horie Y
Kawai S
Okuda H
Terazawa T
Kondoh C
Kato K
Yoshimura K
Ishikawa H
Hamamoto Y
Boku N
Takaishi H
Kanai T

巻: 19
号: 1
開始ページ: 13
終了ページ: 21
記述言語: 英語
掲載種別
DOI: 10.1016/j.clcc.2019.10.004
出版者・発行元: Clinical Colorectal Cancer

© 2019 Elsevier Inc. To improve the tolerability and maintain sufficient efficacy of regorafenib, we conducted a phase II study of regorafenib with a lower starting dose of 120 mg/day for patients with refractory metastatic colorectal cancer. Using this dose-escalation strategy, the disease control rate for the 68 evaluable patients was lower than that in our statistical hypothesis, and a relationship of unbound exposure with toxicity was observed.

リンク情報

DOI: https://doi.org/10.1016/j.clcc.2019.10.004
PubMed: https://www.ncbi.nlm.nih.gov/pubmed/31732439
URL: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85075332951&origin=inward

ID情報

DOI : 10.1016/j.clcc.2019.10.004
ISSN : 1533-0028
PubMed ID : 31732439

エクスポート: BibTeX RIS

浜本康夫

論文

A Phase II Study of Regorafenib With a Lower Starting Dose in Patients With Metastatic Colorectal Cancer: Exposure–Toxicity Analysis of Unbound Regorafenib and Its Active Metabolites (RESET Trial)

メニュー